Chemical engineering at the antibody hinge

Chemical Immunology

Volumn 65, Issue , 1997, Pages 57-72

  Stevenson, George T ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY;

ANTIBODY STRUCTURE; ARTICLE; CHEMICAL ENGINEERING; DISULFIDE BOND; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; CHEMICAL ENGINEERING; DISULFIDES; HUMANS; IMMUNOGLOBULIN CONSTANT REGIONS; IMMUNOGLOBULIN FAB FRAGMENTS; PROTEIN CONFORMATION;

EID: 0031036285     PISSN: 10150145     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Stevenson GT, Glennie MJ, Kan KS: Chemically engineered chimaeric and multi-Fab antibodies, in Clark M (ed): Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man. Nottingham, Academic Titles, 1993, pp 127-141.
2. King DJ, Turner A, Farnsworth APH, Adair JR, Owens RJ, Pedley RB, Baldock D, Proudfoot KA, Lawson ADG, Beeley NRA, Millar K, Millican TA, Boyce BA, Antoniw P, Mountain A, Begent RHJ, Shochat D, Yarranton GT: Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 1994;54:6176-6185.
3. Seegan GW, Smith CA, Schumaker VN: Changes in quaternary structure of IgG upon reduction of the interheavy-chain disulfide bond. Proc Natl Acad Sci USA 1979;76:907-911.
4. Isenman DE, Dorrington KJ, Painter RH: The structure and function of immunoglobulin domains. II. The importance of interchain disulfide bonds and the possible role of molecular flexibility in the interaction between immunoglobulin G and complement. J Immunol 1975;114:1726-1729.
5. Fujio H, Karush F: Antibody affinity. II. Effect of immunization interval on antihapten antibody in the rabbit. Biochemistry 1966;5:1856-1863.
6. Ashman RF, Metzger H: A Waldenström macroglobulin which binds nitrophenyl ligands. J Biol Chem 1969;244:3405-3411.
7. Padlan EA: Anatomy of the antibody molecule. Mol Immunol 1994;31:169-217.
8. Parham P: On the fragmentation of monoclonal IgG1, IgG2a and IgG2b from BALB/c mice. J Immunol 1983;131:2895-2902.
9. Yamaguchi Y, Kim H, Kato K, Masuda K, Shimada I, Arata Y:Proteolytic fragmentation with high specificity of mouse immunoglobulin G. Mapping of proteolytic cleavage sites in the hinge region. J Immunol Methods 1995;181:259-267.
10. Liu TY: The role of sulfur in proteins: in Neurath H (ed): The Proteins. New York, Academic Press. 1977, pp 239-402.
11. Cecil R, McPhee JR: The sulfur chemistry of proteins. Adv Protein Chem 1959;14:255-389.
12. Cleland WW: Dithiothreitol, a new protective reagent for SH groups. Biochemistry 1964;4:480-482.
13. Grassetti, DR, Murray Jr JF: Determination of sulfhydryl groups with 2,2′-or 4,4′-dithiopyridine. Arch Biochem Biophys 1967;119:41-49.
14. Brocklehurst K: Specific covalent modification of thiols: Applications in the study of enzymes and other biomolecules. Int J Biochem 1979;10:259-274.
15. Grimshaw CE, Whistler RL, Cleland WW: Ring opening and closing rates for thiosugars. J Am Chem Soc 1979;101:1521-1532.
16. Hamblin TJ, Cattan AR, Glennie MJ, MacKenzie MR, Stevenson FK, Watts HF, Stevenson GT: Initial experience in treating human lymphoma with a chimeric univalent derivative of monoclonal anti-idiotype antibody. Blood 1987;69:790-797.
17. 2 antibody containing thioether-linked Fab′γ fragments. J Immunol 1987;139:2367-2375.
18. Schott ME, Frazier KA, Pollock DK, Verbanac KM: Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumor antibody fragments. Bioconjugate Chem 1993;4:153-165.
19. Vitetta ES, Thorpe PE, Uhr JW: Immunotoxins - magic bullets or misguided missiles. Trends Pharmacol Sci 1993;14:148-154.
20. Wawrzynczak EJ, Cumber AJ, Henry RV, Parnell GD, Westwood JH: Structural factors influencing the pharmacokinetics and stability of immunotoxins. Biochem Soc Trans 1992;20:738-743.
21. Lane AC, Foroozan S, Glennie MJ, Kowalski-Saunders P, Stevenson GT: Enhanced modulation of antibodies coating guinea pig leukemic cells in vitro and in vivo. The role of FCγR expressing cells. J Immunol 1991;146:2461-2468.
22. Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, Donnall Thomas E: Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987;69:584-591.
23. Stevenson GT, Pindar A, Slade AJ: A chimeric antibody with dual Fc regions (bisFabfc) prepared by manipulations at the IgG hinge. Anti-Cancer Drug Design 1989;3:219-230.
24. Caron PC, Laird W, Sung Co M, Avdalovic NM, Queen C, Scheinberg DA: Engineered humanized dimeric forms of IgG are more effective antibodies. J Exp Med 1992;176:1191-1195.
25. Smith RIF, Morrison SL: Recombinant polymeric IgG: An approach to engineering more potent antibodies. Biotechniques 1994;12:683-688.